Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.

MLA

Stukas, Darius, et al. “Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.” International Journal of Molecular Sciences, vol. 24, no. 17, Aug. 2023. EBSCOhost, https://doi.org/10.3390/ijms241713155.

APA

Stukas, D., Jasukaitiene, A., Bartkeviciene, A., Matthews, J., Maimets, T., Teino, I., Jaudzems, K., Gulbinas, A., & Dambrauskas, Z. (2023). Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway. International Journal of Molecular Sciences, 24(17). https://doi.org/10.3390/ijms241713155

Chicago

Stukas, Darius, Aldona Jasukaitiene, Arenida Bartkeviciene, Jason Matthews, Toivo Maimets, Indrek Teino, Kristaps Jaudzems, Antanas Gulbinas, and Zilvinas Dambrauskas. 2023. “Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.” International Journal of Molecular Sciences 24 (17). doi:10.3390/ijms241713155.